title: Rare adverse events due to house dust mite sublingual immunotherapy in pediatric practice: two case reports.
abstract: Sublingual route, a noninjective way of allergen administration appears to be associated with a lower incidence of severe systemic reactions compared with the subcutaneous route. Local adverse reactions are reported which resolve spontaneously within a few days without need for discontinuation of treatment. Hereby, we report two pediatric cases, one with persistent asthma and the other one with persistent allergic rhinitis. Both were treated by house dust mite sublingual immunotherapy, one of whom developed severe wheezing (grade 2 systemic reaction based on World Allergy Organization subcutaneous systemic reaction grading system) and the other intractable vomiting (grade 3 local reaction based on World Allergy Organization sublingual immunotherapy local adverse events grading system) at the end of the build-up phase which repeated on re-administration of the same dose. Both of those two cases completed their 3-year immunotherapy successfully by patient-based adjustment of the highest tolerated dose of the maintenance.
authors.affiliation: Division of Pediatric Allergy & Clinical Immunology, Near East University Hospital, Near East Avenue, Nicosia, North Cyprus, Mersin 10 Turkey.
authors.forename: Nilufer
authors.initials: N
authors.lastname: Galip
authors.affiliation: Division of Pediatric Allergy & Clinical Immunology, Near East University Hospital, Near East Avenue, Nicosia, North Cyprus, Mersin 10 Turkey.
authors.forename: Nerin
authors.initials: N
authors.lastname: Bahceciler
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D040001:Dermatophagoides farinae / Q000276:immunology*; D040002:Dermatophagoides pteronyssinus / Q000276:immunology*; D004306:Dose-Response Relationship, Immunologic; D000068298:Fluticasone / Q000627:therapeutic use; D006633:Histamine Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D009325:Nausea / Q000276:immunology; D012135:Respiratory Sounds / Q000276:immunology; D065631:Rhinitis, Allergic / Q000188:drug therapy / Q000628:therapy*; D063729:Sublingual Immunotherapy / Q000009:adverse effects*; D014839:Vomiting / Q000276:immunology
chemical_list: D006633:Histamine Antagonists; D000068298:Fluticasone
keywords: adverse event; house dust mite; sublingual immunotherapy